Diagnosis and disease modifying treatments in multiple sclerosis
Author:
Open Access
- 1 September 2005
- journal article
- review article
- Published by Oxford University Press (OUP)
- Vol. 81 (959) , 556-561
Abstract
Multiple sclerosis (MS) refers to scattered areas of hardening found on sectioning central nervous system tissue of affected people, usually after many years of illness. It rarely causes early death but is the commonest cause of neurological disability among young people. Overall results from controlled trials over the past 50 years have been rather disappointing but the comparatively recent licensing of drugs such as interferon beta and glatiramer acetate has led to a reappraisal of many aspects of MS. There are now new diagnostic criteria, which encompass developments in magnetic resonance imaging. Older clinical methods of measuring disease impact are now being re-evaluated to facilitate clinical trials of the approximate 150 new products currently being developed as potential disease modifying agents. The success and failure of agents that should be effective on theoretical grounds, together with advances in neuropathology, have led to fundamental questions regarding our basic understanding of disease pathogenesis being re-addressed.Keywords
This publication has 32 references indexed in Scilit:
- Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesionAnnals of Neurology, 2004
- Neuroprotection in Parkinson's disease: Clinical trialsAnnals of Neurology, 2003
- Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosisBMJ, 2003
- A quantitative analysis of oligodendrocytes in multiple sclerosis lesionsBrain, 1999
- Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosisThe Lancet, 1999
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- INTERACTIONS BETWEEN OLIGODENDROCYTES AND MICROGLIABrain, 1992
- Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitroAnnals of Neurology, 1988